Literature DB >> 23568562

Utility of cardiac magnetic resonance imaging, echocardiography and electrocardiography for the prediction of clinical response and long-term survival following cardiac resynchronisation therapy.

Andris H Ellims1, Heinz Pfluger, Maros Elsik, Michelle J Butler, James L Hare, Andrew J Taylor.   

Abstract

Cardiac resynchronisation therapy (CRT) can reduce symptoms, hospitalisations, and mortality in patients with severe left ventricular (LV) systolic dysfunction and electro-mechanical dyssynchrony. Unfortunately, approximately 30 % of eligible patients fail to respond to CRT. This study prospectively compared electrocardiography (ECG), echocardiography, and cardiac magnetic resonance (CMR) imaging for the prediction of response to CRT. We performed ECG, echocardiography and CMR on 46 patients prior to planned CRT implantation. Patients were divided into predicted responder and non-responder groups using previously described criteria for each modality. Changes in indicators of CRT response were recorded 6 months post-implantation, and later for transplant-free survival. Less dyspnoea, lower levels of N-terminal pro-brain natriuretic peptide, more LV reverse remodelling, and longer transplant-free survival were observed in predicted responders compared to predicted non-responders using each of the three modalities (p < 0.05 for each comparison). Additionally, for patients with QRS duration <150 ms and/or non-left bundle branch block (non-LBBB) QRS morphology, CMR predicted both clinical response and improved longer term transplant-free survival (80 % transplant-free survival in predicted responders vs. 20 % in predicted non-responders, p = 0.04). ECG and cardiac imaging techniques predict improvements in markers of response following CRT with similar accuracy. However, for CRT candidates with shorter, non-LBBB QRS complexes, a subgroup known to derive less benefit from CRT, CMR may predict those who are more likely to gain both symptomatic and survival benefits.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23568562     DOI: 10.1007/s10554-013-0215-9

Source DB:  PubMed          Journal:  Int J Cardiovasc Imaging        ISSN: 1569-5794            Impact factor:   2.357


  28 in total

1.  Echocardiographic modeling of cardiac dyssynchrony before and during multisite stimulation: a prospective study.

Authors:  S Cazeau; P Bordachar; G Jauvert; A Lazarus; C Alonso; M C Vandrell; J Mugica; P Ritter
Journal:  Pacing Clin Electrophysiol       Date:  2003-01       Impact factor: 1.976

2.  Left ventricular dyssynchrony predicts benefit of cardiac resynchronization therapy in patients with end-stage heart failure before pacemaker implantation.

Authors:  Jeroen J Bax; Thomas H Marwick; Sander G Molhoek; Gabe B Bleeker; Lieselot van Erven; Eric Boersma; Paul Steendijk; Ernst E van der Wall; Martin J Schalij
Journal:  Am J Cardiol       Date:  2003-11-15       Impact factor: 2.778

3.  2010 Focused Update of ESC Guidelines on device therapy in heart failure: an update of the 2008 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure and the 2007 ESC guidelines for cardiac and resynchronization therapy. Developed with the special contribution of the Heart Failure Association and the European Heart Rhythm Association.

Authors:  Kenneth Dickstein; Panos E Vardas; Angelo Auricchio; Jean-Claude Daubert; Cecilia Linde; John McMurray; Piotr Ponikowski; Silvia Giuliana Priori; Richard Sutton; Dirk J van Veldhuisen
Journal:  Eur Heart J       Date:  2010-08-27       Impact factor: 29.983

4.  Greater three-dimensional ventricular lead tip separation is associated with improved outcome after cardiac resynchronization therapy.

Authors:  Rina Ariga; Muzahir H Tayebjee; Anne Benfield; Michelle Todd; David C Lefroy
Journal:  Pacing Clin Electrophysiol       Date:  2010-10-08       Impact factor: 1.976

5.  Delayed enhancement magnetic resonance imaging predicts response to cardiac resynchronization therapy in patients with intraventricular dyssynchrony.

Authors:  James A White; Raymond Yee; Xiaping Yuan; Andrew Krahn; Allan Skanes; Michele Parker; George Klein; Maria Drangova
Journal:  J Am Coll Cardiol       Date:  2006-10-31       Impact factor: 24.094

6.  ACC/AHA/HRS 2008 Guidelines for Device-Based Therapy of Cardiac Rhythm Abnormalities: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the ACC/AHA/NASPE 2002 Guideline Update for Implantation of Cardiac Pacemakers and Antiarrhythmia Devices): developed in collaboration with the American Association for Thoracic Surgery and Society of Thoracic Surgeons.

Authors:  Andrew E Epstein; John P DiMarco; Kenneth A Ellenbogen; N A Mark Estes; Roger A Freedman; Leonard S Gettes; A Marc Gillinov; Gabriel Gregoratos; Stephen C Hammill; David L Hayes; Mark A Hlatky; L Kristin Newby; Richard L Page; Mark H Schoenfeld; Michael J Silka; Lynne Warner Stevenson; Michael O Sweeney; Sidney C Smith; Alice K Jacobs; Cynthia D Adams; Jeffrey L Anderson; Christopher E Buller; Mark A Creager; Steven M Ettinger; David P Faxon; Jonathan L Halperin; Loren F Hiratzka; Sharon A Hunt; Harlan M Krumholz; Frederick G Kushner; Bruce W Lytle; Rick A Nishimura; Joseph P Ornato; Richard L Page; Barbara Riegel; Lynn G Tarkington; Clyde W Yancy
Journal:  Circulation       Date:  2008-05-15       Impact factor: 29.690

7.  Effect of QRS duration and morphology on cardiac resynchronization therapy outcomes in mild heart failure: results from the Resynchronization Reverses Remodeling in Systolic Left Ventricular Dysfunction (REVERSE) study.

Authors:  Michael R Gold; Christophe Thébault; Cecilia Linde; William T Abraham; Bart Gerritse; Stefano Ghio; Martin St John Sutton; Jean-Claude Daubert
Journal:  Circulation       Date:  2012-07-10       Impact factor: 29.690

8.  The effect of cardiac resynchronization on morbidity and mortality in heart failure.

Authors:  John G F Cleland; Jean-Claude Daubert; Erland Erdmann; Nick Freemantle; Daniel Gras; Lukas Kappenberger; Luigi Tavazzi
Journal:  N Engl J Med       Date:  2005-03-07       Impact factor: 91.245

9.  Magnetic resonance imaging and response to cardiac resynchronization therapy: relative merits of left ventricular dyssynchrony and scar tissue.

Authors:  Nina Ajmone Marsan; Jos J M Westenberg; Claudia Ypenburg; Rutger J van Bommel; Stijntje Roes; Victoria Delgado; Laurens F Tops; Rob J van der Geest; Eric Boersma; Albert de Roos; Martin J Schalij; Jeroen J Bax
Journal:  Eur Heart J       Date:  2009-07-04       Impact factor: 29.983

10.  Randomised trial of low-dose amiodarone in severe congestive heart failure. Grupo de Estudio de la Sobrevida en la Insuficiencia Cardiaca en Argentina (GESICA)

Authors:  H C Doval; D R Nul; H O Grancelli; S V Perrone; G R Bortman; R Curiel
Journal:  Lancet       Date:  1994-08-20       Impact factor: 79.321

View more
  4 in total

Review 1.  Cardiovascular imaging 2013 in the International Journal of Cardiovascular Imaging.

Authors:  Hiram G Bezerra; Ricardo A Costa; Johan H C Reiber; Frank J Rybicki; Paul Schoenhagen; Arthur A Stillman; Johan De Sutter; Nico R L Van de Veire
Journal:  Int J Cardiovasc Imaging       Date:  2014-04       Impact factor: 2.357

2.  The postimplantation electrocardiogram predicts clinical response to cardiac resynchronization therapy.

Authors:  Edward Coverstone; Justin Sheehy; Robert E Kleiger; Timothy W Smith
Journal:  Pacing Clin Electrophysiol       Date:  2015-03-16       Impact factor: 1.976

Review 3.  Cardiac Imaging in Heart Failure with Comorbidities.

Authors:  Chiew Wong; Sylvia Chen; Pupalan Iyngkaran
Journal:  Curr Cardiol Rev       Date:  2017

4.  Regional contributions to left ventricular stroke volume determined by cardiac magnetic resonance imaging in cardiac resynchronization therapy.

Authors:  Björn Östenson; Ellen Ostenfeld; Anna Werther-Evaldsson; Anders Roijer; Zoltan Bakos; Mikael Kanski; Einar Heiberg; Håkan Arheden; Rasmus Borgquist; Marcus Carlsson
Journal:  BMC Cardiovasc Disord       Date:  2021-10-26       Impact factor: 2.298

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.